



Pharmacy and Therapeutics Committee

August 16, 2016 12:00pm -5:00 pm
Gold Room, 3rd Floor
701 E. Jefferson Phoenix, AZ 85034

AGENDA

Teleconference: 1-877-820-7831 Passcode: 778195

Agenda Topics

Noon

Welcome and Introductions: Sara Salek, MD, Chief Medical Officer, AHCCCS

- 5-17-16 P&T Minutes Review and Vote
- P&T Operational Policy Review and Vote

AHCCCS and BH Drug Lists

12:15

Supplemental Rebate Class Review:

1. Atypical Antipsychotics (oral and long-acting injectables)
 - a. Clinical review: Sarah Martinez: Provider Synergies
 - b. Pharma Testimony Oral:
 - i. Amy Everitt: Sunovion: Latuda
 - ii. Kristin Pareja: Otsuka: Rexulti
 - c. Pharma Testimony Long-acting Injectables
 - i. Kristin Pareja: Otsuka: Abilify Maintena
 - ii. Deborah Profant: Alkermes: Aristada
 - iii. Laura Litzenberger: Janssen Scientific Affairs: Invega Sustenna & Invega Trinza
 - d. Public Testimony:
 - i. John Sarris
 - ii. William Sullivan II
 - iii. Deni Nordmeyer
 - iv. Carol Olson
 - v. Charles Goldstein
 - vi. Kristina Sabetta
 - vii. H. Clarke Romans
 - viii. Elizabeth Kosloff
 - ix. Joy Green
 - x. Thomas Gazda
 - xi. Frank Lovecchio
 - xii. Ron Dominquez
2. Stimulants and Related Agents
 - a. Clinical review: Sarah Martinez: Provider Synergies
 - b. Pharma Testimony:
 - i. Erin Miller: Shire: Vyvanse & Adderall XR
 - c. Public Testimony:
3. Anticoagulants
 - a. Clinical review: Sarah Martinez: Provider Synergies
 - b. Pharma Testimony
 - i. Jon Glover: BMS/Pfizer: Eliquis
 - ii. William Oneill: Boehringer-Ingelheim: Pradaxa
 - iii. Laura Litzenberger: Janssen Scientific Affairs: Xarelto
 - c. Public Testimony

	<ul style="list-style-type: none"> i. Govardhanan Nagaiah ii. Jan Prasad <p>4. Pancreatic Enzymes</p> <ul style="list-style-type: none"> a. Clinical review: Sarah Martinez: Provider Synergies b. Pharma Testimony: c. Public Testimony <p>5. Epclusa</p> <ul style="list-style-type: none"> a. Clinical review: Sarah Martinez: Provider Synergies b. Pharma Testimony <ul style="list-style-type: none"> i. Coleen Fong, Gilead, Epclusa c. Public Testimony <p>6. Executive Session</p> <p>7. Class Votes</p>
	<p>BH Drug List: <i>Sara Salek, MD, AHCCCS</i> Options for Drug List Management Prior Authorization Criteria Approach</p>
	<p>Follow up Oral Oncology Agents drug list management approach-- <i>Sara Salek, MD, AHCCCS</i></p>
	<p>Follow up: Genvoya PA status— <i>Sara Salek, MD, AHCCCS</i></p>
	<p>Follow up: Insulin Pens—Suzi Berman</p>
	<p>New Drug Reviews: Non-Supplemental Rebate Class: <i>Sarah Martinez, Provider Synergies</i></p> <ul style="list-style-type: none"> 1. Cabometyx - Cabozantinib 2. Descovy – Emtricitabine & Tenofovir Alafenamide Fumarate 3. Odefsey - Emtricitabine, Rilpivirine & Tenofovir Alafenamide Fumarate 4. Taltz - Ixekizumab 5. Veltassa - Patiromer Sorbitex Calcium 6. Venclexta – Venetoclax
4:55	<p>Agenda Items for October 19, 2016 P&T: Drug classes for review at the next P&T Committee include: Antibiotics, Inhaled: Cytokine & CAM Antagonists: Epinephrine Self-Injected: Growth Hormone: Long-Acting Narcotic Analgesics</p>
5:00	<p>Meeting Adjourned</p>

2016 Next Meeting Date:

Wednesday, October 19, 2016

2017 Meeting Dates:

Monday, January 16, 2017, Thursday, April 13, 2017, Tuesday, July 18, 2017, & Thursday, October 12, 2017